ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

BIAXIN
Bacterial infections
Hyperacidity, GERD, and ulcers
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

BIAXIN Rx

Generic Name and Formulations:
Clarithromycin 250mg, 500mg; tabs.

Company:
AbbVie

Therapeutic Use:

Indications for BIAXIN:

Mild to moderate susceptible pharyngitis/tonsillitis, acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, acute maxillary sinusitis, acute otitis media, uncomplicated skin and skin structure infections. Disseminated M. intracellulare. Treatment (with other antimycobacterials) and prophylaxis of disseminated Mycobacterium avium complex (MAC).

Adult:

Pharyngitis/tonsillitis: 250mg every 12 hours for 10 days. Bronchitis: 250mg–500mg every 12 hours for 7–14 days. CAP, skin and skin structures: 250mg every 12 hours for 7–14 days. Sinusitis: 500mg every 12 hours for 14 days. MAC: 500mg every 12 hours continue indefinitely if improvement occurs. CrCl <30mL/min: ½ dose. Concomitant atazanavir: ½ dose; consider alternative antibacterial therapy for indications other than MAC. Concomitant ranitidine bismuth citrate: not recommended if CrCl <25mL/min.

Children:

<6 months: not recommended. Otitis media, pharyngitis/tonsillitis, pneumonia, sinusitis, skin and skin structures: 7.5mg/kg every 12 hours for 10 days. MAC (see full labeling): 7.5mg/kg every 12 hours; max 500mg twice daily, continue indefinitely if improvement occurs. CrCl <30mL/min: ½ dose. Concomitant atazanavir: ½ dose; consider alternative antibacterial therapy for indications other than MAC. Concomitant ranitidine bismuth citrate: not recommended if CrCl <25mL/min.

See Also:

BIAXIN ORAL SUSPENSION

BIAXIN XL

Contraindications:

Concomitant cisapride, pimozide, ergots, HMG-CoA reductase inhibitors extensively metabolized by CYP3A4 (lovastatin or simvastatin). History of QT prolongation or ventricular cardiac arrhythmia (including torsades de pointes). Concomitant colchicine (in renal or hepatic impairment). Cholestatic jaundice/hepatic dysfunction with prior clarithromycin use.

Warnings/Precautions:

Discontinue immediately if hepatitis or severe hypersensitivity reactions occurs. Severe renal impairment. Proarrhythmic conditions (eg, hypokalemia, hypomagnesemia, bradycardia); avoid. Myasthenia gravis. History of porphyria; avoid concomitant ranitidine bismuth citrate. Elderly. Pregnancy (Cat.C): usually not recommended. Nursing mothers.

Interactions:

See Contraindications. Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmics: not recommended. Sildenafil, tadalafil, vardenafil: not recommended. Antagonized by CYP3A inducers (eg, efavirenz, nevirapine, rifampicin, rifabutin, rifapentine, etravirine); use alternative antibacterial treatment. Doses >1000mg/day should not be coadministered with protease inhibitors. Concomitant atazanavir: reduce clarithromycin dose by 50%. Separate zidovudine dose by at least 2hrs. Potentiated by CYP3A inhibitors (eg, itraconazole, saquinavir). May potentiate theophylline, omeprazole, phenytoin, digoxin, midazolam, alprazolam, triazolam, cyclosporine, hexobarbital, tacrolimus, alfentanil, disopyramide, bromocriptine, valproate, carbamazepine, tolterodine, itraconazole, methylprednisolone, cilostazol, vinblastine; monitor these and other drugs metabolized by CYP3A. Myopathy/rhabdomyolysis with statins; max 20mg atorvastatin/day, 40mg pravastatin/day; consider use of statin not dependent on CYP3A metabolism (eg, fluvastatin). Reduce colchicine dose if coadministration is necessary. Hypoglycemia with oral hypoglycemics/insulin; carefully monitor glucose. Oral anticoagulants: frequently monitor INR and prothrombin times. Hypotension with calcium channel blockers metabolized by CYP3A4 (eg, verapamil, amlodipine, diltiazem).

Adverse Reactions:

Diarrhea, vomiting, dyspepsia, nausea, abdominal pain, abnormal taste, headache, insomnia, rash, increased BUN; hepatotoxicity, QT prolongation, C. difficile associated diarrhea, hypersensitivity reactions.

Metabolism:

Hepatic.

Elimination:

Renal.

How Supplied:

XL tabs, tabs—60; Biaxin XL-Pac (14 x 500mg XL tabs)—4; Susp—50mL, 100mL

BIAXIN

  • 250mg tablets (Qty:30)
  • appx. price $249.00
GoodRx

Indications for BIAXIN:

Triple therapy (w. amoxicillin + lansoprazole or omeprazole) for treating patients with H. pylori infection and duodenal ulcer disease. Dual therapy (w. omeprazole) for treating active duodenal ulcer associated with H. pylori infection.

Adult:

Triple therapy: clarithromycin 500mg + lansoprazole 30mg + amoxicillin 1g, all every 12 hours for 10 or 14 days. Or, clarithromycin 500mg + omeprazole 20mg + amoxicillin 1g, all every 12 hours for 10 days; may continue omeprazole for days 11–28 if ulcer was present at start. Dual therapy: clarithromycin 500mg 3 times daily + omeprazole 40mg once daily in the AM on days 1–14, then omeprazole 20mg once daily in the AM on days 15–28. CrCl <30mL/min: reduce clarithromycin dose by ½. Concomitant ranitidine bismuth citrate: not recommended if CrCl <25mL/min.

Children:

Not recommended.

Pharmacological Class:

Macrolide.

Contraindications:

Concomitant cisapride, pimozide, ergots, HMG-CoA reductase inhibitors extensively metabolized by CYP3A4 (lovastatin or simvastatin). History of QT prolongation or ventricular cardiac arrhythmia (including torsades de pointes). Concomitant colchicine (in renal or hepatic impairment). Cholestatic jaundice/hepatic dysfunction with prior clarithromycin use.

Warnings/Precautions:

Discontinue immediately if hepatitis or severe hypersensitivity reactions occurs. Severe renal impairment. Proarrhythmic conditions (eg, hypokalemia, hypomagnesemia, bradycardia); avoid. Myasthenia gravis. History of porphyria; avoid concomitant ranitidine bismuth citrate. Elderly. Pregnancy (Cat.C): usually not recommended. Nursing mothers.

Interactions:

See Contraindications. Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmics: not recommended. Sildenafil, tadalafil, vardenafil: not recommended. Antagonized by CYP3A inducers (eg, efavirenz, nevirapine, rifampicin, rifabutin, rifapentine, etravirine); use alternative antibacterial treatment. Doses >1000mg/day should not be coadministered with protease inhibitors. Concomitant atazanavir: reduce clarithromycin dose by 50%. Separate zidovudine dose by at least 2hrs. Potentiated by CYP3A inhibitors (eg, itraconazole, saquinavir). May potentiate theophylline, omeprazole, phenytoin, digoxin, midazolam, alprazolam, triazolam, cyclosporine, hexobarbital, tacrolimus, alfentanil, disopyramide, bromocriptine, valproate, carbamazepine, tolterodine, itraconazole, methylprednisolone, cilostazol, vinblastine; monitor these and other drugs metabolized by CYP3A. Myopathy/rhabdomyolysis with statins; max 20mg atorvastatin/day, 40mg pravastatin/day; consider use of statin not dependent on CYP3A metabolism (eg, fluvastatin). Reduce colchicine dose if coadministration is necessary. Hypoglycemia with oral hypoglycemics/insulin; carefully monitor glucose. Oral anticoagulants: frequently monitor INR and prothrombin times. Hypotension with calcium channel blockers metabolized by CYP3A4 (eg, verapamil, amlodipine, diltiazem).

Adverse Reactions:

Diarrhea, vomiting, dyspepsia, nausea, abdominal pain, abnormal taste, headache, insomnia, rash, increased BUN; hepatotoxicity, QT prolongation, C. difficile associated diarrhea, hypersensitivity reactions.

Metabolism:

Hepatic.

Elimination:

Renal.

Note:

See Prilosec entry for more information on omeprazole. See Prevacid entry for more information on lansoprazole. See Amoxil entry for more information on amoxicillin.

How Supplied:

Tabs—60

BIAXIN

  • 250mg tablets (Qty:30)
  • appx. price $249.00
GoodRx

Sign Up for Free e-newsletters